465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
hdm1005 Obesity Disorder	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P3	B (58)
Maridebart Cafraglutide Obesity Disorder	Amgen	P3	B (58)
met097 Obesity Disorder	Pfizer	P3	B (58)
Midazolam Obesity Disorder	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P4	B (58)
nnc0487-0111 Obesity Disorder	Novo Nordisk A/S	P3	B (58)
pf-08653944 Obesity Disorder	Pfizer	P3	B (58)
Ramifentanyl Obesity Disorder	Siirt Training and Research Hospital	P4	B (58)
ray1225 Obesity Disorder	Guangdong Raynovent Biotech Co., Ltd	P3	B (58)
Ropivacaine Obesity Disorder	Ain Shams University	P4	B (58)
Sacubitril Valsartan Obesity Disorder	University of Alabama at Birmingham	P4	B (58)
Sevoflurane Obesity Disorder	Ataturk University	P4	B (58)
Apitegromab Obesity Disorder	Scholar Rock, Inc.	P2	B (57)
Calcined Magnesia Obesity Disorder	Coordinación de Investigación en Salud, Mexico	P3	B (57)
Efsubaglutide Alfa Injection Obesity Disorder	Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.	P2/3	B (57)
gv101 Obesity Disorder	Graviton Bioscience Corporation	P2	B (57)
Human Faecal Matter Obesity Disorder	Institut Pasteur	P2	B (57)
Irbesartan Obesity Disorder	Hippocration General Hospital	P4	B (57)
Langlenatide Obesity Disorder	Hanmi Pharmaceutical Company Limited	P3	B (57)
met233 Obesity Disorder	Pfizer	P1/2	B (57)
ng101 Obesity Disorder	Neurogastrx, Inc.	P2	B (57)
Pitavastatin Obesity Disorder	Hoffmann-La Roche	P3	B (57)
Rose-010 Obesity Disorder	Rose Pharma Inc	P2	B (57)
Tern-601 Obesity Disorder	Terns, Inc.	P2	B (57)
Colchicinum Obesity Disorder	Donders Centre for Cognitive Neuroimaging	P2	B (56)
Danuglipron Obesity Disorder	Pfizer	P2	B (56)
Eudemine Injection Obesity Disorder	Columbia University	P2	B (56)
Heparin Obesity Disorder	National and Kapodistrian University of Athens	P4	B (56)
Intralipid Obesity Disorder	Yale University	P2/3	B (56)
Ixekizumab Obesity Disorder	NHS Greater Glasgow and Clyde	P3	B (56)
Lamivudine Obesity Disorder	José Antonio Mata Marín	P4	B (56)
Magnesium Metallicum Obesity Disorder	University of Sao Paulo General Hospital	P3	B (56)
Umbellatine Obesity Disorder	China National Center for Cardiovascular Diseases	P4	B (56)
Flavone, 3,3',4',5,7-Pentahydroxy- Obesity Disorder	Cedars-Sinai Medical Center	P2/3	CCC (55)
Insulin Detemir Obesity Disorder	Vanderbilt University	P4	CCC (55)
Methylphenidate Obesity Disorder	University Hospital, Tours	P4	CCC (55)
Physiologic Sodium Chloride Solution Obesity Disorder	Cambridge University Hospitals NHS Foundation Trust	P4	CCC (55)
Tenofovir Disoproxil Fumarate Obesity Disorder	José Antonio Mata Marín	P4	CCC (55)
Aleniglipron Obesity Disorder	Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics	P3	CCC (54)
Allopurinol Obesity Disorder	XueMei Guo	P3	CCC (54)
Alpha Tocopherol Obesity Disorder	Bioagile Therapeutics Pvt. Ltd.	P3	CCC (54)
Biktarvy Obesity Disorder	East Carolina University	P4	CCC (54)
Cagrisema Obesity Disorder	Novo Nordisk A/S	P3	CCC (54)
Clinisol 15% Obesity Disorder	Mayo Clinic	P4	CCC (54)
Dextrose Obesity Disorder	Mayo Clinic	P4	CCC (54)
Erythromycin Obesity Disorder	Universitaire Ziekenhuizen KU Leuven	P4	CCC (54)
Esomeprazole Obesity Disorder	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P4	CCC (54)
Imipenem Obesity Disorder	University of Illinois at Chicago	P4	CCC (54)
Megestrol Acetate Obesity Disorder	Xiaojun Chen	P2/3	CCC (54)
Metyrapone Obesity Disorder	Eleonora Seelig	P4	CCC (54)
Niacin Obesity Disorder	Université de Sherbrooke	P2	CCC (54)

Showing 101 to 150 of 465 assets

PreviousPage 3 of 10Next